Неоадъювантное и постнеоадъювантное лечение трижды негативного рака молочной железы


DOI: https://dx.doi.org/10.18565/pharmateca.2020.11.8-13

В.Ф. Семиглазов, М.А. Джелялова, А.И. Целуйко, Р.С. Песоцкий, А.А. Бессонов, Т.Ю. Семиглазова

Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия
Трижды негативный рак является подтипом рака молочной железы (РМЖ), характеризующимся отсутствием экспрессии рецепторов эстрогенов, прогестерона, а также отсутствием сверхэкспресии HER2 и его амплификации. Трижды негативный рак молочной железы (ТНРМЖ) составляет 10–20% от всех случаев РМЖ, при этом несколько чаще по сравнению с гормон-рецептор-позитивным заболеванием встречается среди пациенток молодого возраста и характеризуется более агрессивным течением, ранними рецидивами. Несмотря на массу исследований на данную тему, стандартом лечения этого заболевания остается только химиотерапия ввиду отсутствия каких-либо мишеней на поверхности опухоли, доступных для воздействия. В связи с агрессивностью заболевания предпринимается множество попыток улучшения результатов лечения пациенток с ТНРМЖ. К ним относятся использование постнеоадъювантной терапии, добавление препаратов платины, использование дозоуплотнительных режимов, применение PARP-ингибиторов и поиск различных биомаркеров для выявления пациенток, к которым можно было бы применить дополнительные варианты терапии. В данном обзоре будут рассмотрены результаты современных испытаний по озвученным темам.

Литература


1. Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59. Doi: 10.1056/NEJMoa1612645.


2. Kuroi K., Toi M., Ohno S., et al. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 2015;22:486–95. https://doi.org/10.1007/s12282-013-0511-1


3. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. N Engl J Med. 2005;352:2696–704. Doi: 10.1056/NEJMoa043116.


4. Bang Y.J., Kim Y.W., Yang H.K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. Doi: 10.1016/S0140-6736(11)61873-4.


5. Noh S.H., Park S.R., Yang H.K., et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet. Oncol. 2014;15(12):1389–96. Doi: 10.1016/S1470-2045(14)70473-5.


6. Martin M., Ruiz S.A., Ruiz B.M., et al. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. J Clin Oncol. 2015;33(32):3788–95. Doi: 10.1200/JCO.2015.61.9510.


7. Joensuu H., Kellolumpu-Lehtinen P.L., Huovinen R.,et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11–8. Doi: 10.1200/JCO.2011.35.4639.


8. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485–93. Doi: 10.1200/JCO.1999.17.2.485.


9. Miles D., von Minckwitz G., Seidman A.D., et al. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist. 2002;7(Suppl. 6):13–9.


10. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2006;355:2733–43. Doi: 10.1056/NEJMoa064320.


11. O’Shaughnessy J., Koeppen H., Xiao Y., et al. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin. Cancer Res. 2015;21(19):4305–11. Doi: 10.1158/1078-0432.CCR-15-0636.


12. Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59. Doi: 10.1056/NEJMoa1612645.


13. Toi M., Atiqur Rahman М., Bando H., Chow L.W. Thymidine phosphorylase (plateletderived endothelial-cell growth factor) in cancer biology and treatment. Lancet. Oncol. 2005;6:158–66. Doi: 10.1016/S1470-2045(05)01766-3.


14. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemothe arable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84. Doi: 10.1056/NEJMoa052122.


15. Sparano J.A., Zhao R., Martino S., et al. Long-term follow-up of the Е 1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015;33:2353–60. Doi: 10.1200/JCO.2015.60.9271.


16. Moebus V., Jackisch С., Lueck H.J., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Oncol. 2010;28:2874–80. Doi: 10.1200/JCO.2009.24.7643.


17. Bear H.D., Tang G., Rastogi P., et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40


18. von Minckwitz G., Rezai M., Loibl S., et al. Capecitabine in addition to anthracycline and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28:2015–23. Doi: 10.1200/JCO.2009.23.8303.


19. Ohno S., Chow L.W., Sato N., et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki-67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2013;142(1):69–80. Doi: 10.1007/s10549-013-2691-y.


20. Cortazar P., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72. Doi: 10.1016/S0140-6736(13)62422-8.


21. Symmans W.R., Peintinger R., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22. Doi: 10.1200/JCO.2007.10.6823.


22. Symmans W.R., Wei C., Gould R., et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and BreastCancer Subtype. J Clin Oncol. 2017;35:1049–60. Doi: 10.1200/JCO.2015.63.1010.


23. Denkert С., von Minckwitz G., Darb-Esfahani S., et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet. Oncol. 2018;19:40–50. Doi: 10.1016/S1470-2045(17)30904-X.


24. Luen S., Solgado R., Died M., et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019;30(2):236–42. Doi: https://doi.org/10.1093/annonc/mdy547.


25. Loi S., Dmbay D., Adams S., et al. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. Cancer Res. 2016;76:Abstract S 1-03. Doi: 10.1200/JCO.18.01010.


26. Dieci M.V., Criscitiello C., Goubar A., et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611–823. Doi: 10.1093/annonc/mdt556.


27. CriscitielJo С., Вауаr M.A., Curigliano G., et al. A gene signature to predict hightumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol. 2018;29:162–69. doi: 10.1093/annonc/mdx691.


28. Hartmann L., Schaid D., Woods J., Crotty T., Myers J. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. Engl J Med. 1999;340(2):77–84. Doi: 10.1056/NEJM199901143400201.


29. Phillips K.A., Lindeman G.J. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? Future Oncol. 2014;10(4):499–502. doi.org/10.2217/fon.13.278


30. Fisher В., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97:1652–62. Doi: 10.1093/jnci/dji372.


31. Cuzick J., Sestak I., Bonanni B., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual. Lancet. 2013;381(9880):1827–34. Doi: 10.1016/S0140-6736(13)60140-3.


32. Metcalfe K., Lynch H.T., Ghadirian Р., et al. Contralateral breast cancer in BRCAl and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–35. Doi: 10.1200/JCO.2004.04.033.


33. Narod S.A. Hormonal prevention of hereditary breast cancer. Ann N Y Acad Sci. 2001;952:36–43. Doi.org/10.1111/j.1749-6632.2001.tb02726.x


34. Farmer H. McCabe N., Lord C.J., et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21. https://doi.org/10.1038/nature03445


35. Robson M., Im S.A., Senkus E., et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. Doi: 10.1056/NEJMoa1706450.


36. Litton J.K., Rugo H.S., Ettl J., et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63. Doi: 10.1056/NEJMoa1802905.


37. Ettl J., Quek R.G.W., Lee K.H., et al: Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial. Ann. Oncol. 2018;29:1939–47. Doi: 10.1093/annonc/mdy257.


38. Burstein H.L., Curigliano G., Loibl S., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–57. Doi: 10.1093/annonc/mdz235.


39. Loibl S., Weber K.E., Timms K.M., et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of responsefinal results from GeparSixto. Ann Oncol. 2018;29(12):2341–47. Doi: 10.1093/annonc/mdy460.


40. Loibl S., Untch M.N., et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 2018;36(suppl):abstr 104. Doi: 10.1200/JCO.2018.36.15_suppl.104.


41. Nanda R., Liu M.C., Yau C., et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (ВС): results from I-SPY2. J Clin Oncol. 2017;35(l5):S506–6. Doi: 10.1200/JCO.2017.35.15_suppl.506.


42. Martin M., Barrios C.H., Torrecilla L., et al. Efficacy results form the CIBOMA 2004-01/ GEICAM 2003-11 study: a randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. SABCS. 2018. Doi: 10.1158/1538-7445.SABCS18-GS2-04.


43. Nitz U., Gluk O., Clegpens М., et al. West German PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2 negative early breast cancer. J Clin Oncol. 2019;37:799–808. Doi: 10.1200/JCO.18.00028.


44. Blum J.L., Flynn P.J., Yothers G., et al. Anthracyclines in early breast cancer: the ABC Trials USOR 06-090, NSABP B-46-1/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35:2647–55. Doi: 10.1200/JCO.2016.71.4147.


45. Robson М., Im S.A., Senkus Е., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. Doi: 10.1056/NEJMoa1706450.


46. Weigelt В., Comino-Mndez I., de Bruijn I., et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin. Cancer Res. 2017;23(21):6708–20. Doi: 10.1158/1078-0432.CCR-17-0544.


47. Kurian A.W., Ward К.С., Howlader N. Genetic Testing and Results in a Population- Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019;37(15):1305–15. Doi: 10.1200/JCO.18.01854.


Об авторах / Для корреспонденции


Автор для связи: М.А. Джелялова, врач-онколог клинико-диагностического отделения, НМИЦ онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия; gub.mariam@gmail.com
Адрес: 197758, Россия, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68


ORCID:
В.Ф. Семиглазов, https://orcid.org/0000-0003-0077-9619
Р.С. Песоцкий, https://orcid.org/0000-0002-2573-2211 
М.А. Джелялова, https://orcid.org/0000-0003-0077-9619
Т.Ю. Семиглазова, https://orcid.org/0000-0002-4305-6691 
А.И. Целуйко, https://orcid.org/0000-0001-8384-5786
А.А. Бессонов, https://orcid.org/0000-0002-6649-7641 


Похожие статьи


Бионика Медиа